文献速递白血病

高三尖杉酯碱联合维奈克拉和阿扎胞苷诱导治疗初诊AML的初步分析

[A preliminary analysis of the efficacy and safety of homoharringtonine, venetoclax, and azacitidine for newly diagnosed acute myeloid leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

该回顾性研究比较VHA与VA方案诱导治疗59例初诊不适合强化疗或老年AML患者的疗效与安全性。两组ORR、MRD转阴率及1年RFS无显著差异,但VHA组1年OS率更高,高危患者中VHA组MRD转阴率、1年RFS和OS均更优。VHA组Ⅲ~Ⅳ级血小板减少发生率更高。

要点

  • VHA与VA方案总体疗效相当,但VHA组1年OS率更高。
  • 高危AML患者中VHA组MRD转阴率及1年RFS、OS均优于VA组。
  • VHA组Ⅲ~Ⅳ级血小板减少发生率更高,但不良反应总体可控。

核心结论

  • VHA方案治疗初诊不适合强化疗及老年AML患者存在临床获益,尤其对于高危患者,序贯allo-HSCT能够获益,且相关不良反应可控。

研究设计与样本

  • 回顾性分析2018年9月至2021年7月郑州大学附属肿瘤医院收治的59例初诊AML患者,男25例、女34例,中位年龄63岁,其中26例接受VHA方案、33例接受VA方案。
  • 比较两组ORR、复合缓解率、MRD、OS、RFS及不良反应,采用Kaplan-Meier法和Cox回归模型进行生存预后单因素及多因素分析。

主要发现

  • VHA组ORR为88.4%(23/26,CR 21例、PR 2例),VA组为90.9%(30/33,CR 25例、PR 5例),差异无统计学意义(P=0.458)。
  • VHA组与VA组1个疗程MRD转阴率分别为73.1%(19/26)和60.6%(20/33),差异无统计学意义(P=0.315)。
  • 高危患者中VHA组与VA组1个疗程复合缓解率分别为78.6%(11/14)和50.0%(5/10),差异无统计学意义(P=0.143);MRD转阴率分别为64.3%(9/14)和20.0%(2/10),差异有统计学意义(P=0.032)。
  • 中位随访13(1~59)个月,VHA组与VA组1年RFS率分别为69.9%(95%CI:53.1%~92.2%)和55.6%(95%CI:40.1%~77.1%),差异无统计学意义(P=0.305);1年OS率分别为91.7%(95%CI:77.3%~100%)和58.2%(95%CI:41.7%~81.4%),差异有统计学意义(P=0.024)。
  • 高危患者中VHA组1年RFS率及OS率均高于VA组(RFS:66.2%对37.5%,P=0.046;OS:85.7%对48.0%,P=0.011);接受allo-HSCT能够明显提高OS率及RFS率(P值分别为0.027、0.047)。

关键数值与推荐

  • 多因素分析显示ELN分层、1个疗程MRD转阴为影响RFS的独立预后因素。
  • 不同用药方案、1个疗程MRD转阴及是否移植为影响OS的独立预后因素。
  • VHA组Ⅲ~Ⅳ级血小板减少发生率高于VA组(76.9%对45.5%,P=0.015);两组Ⅲ~Ⅳ级中性粒细胞减少、血红蛋白减少发生率差异无统计学意义。

临床怎么用

  • 对初诊不适合强化疗及老年AML患者,VHA方案可作为诱导治疗选择,尤其高危患者可能获益更明显。
  • 获得缓解后序贯allo-HSCT可进一步提高生存获益。
  • VHA方案治疗期间需关注Ⅲ~Ⅳ级血小板减少,做好支持治疗。

局限性

  • 本研究为单中心回顾性分析,样本量59例,结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare the efficacy and safety of two induction regimens, homoharringtonine plus venetoclax and azacitidine (VHA) versus venetoclax and azacitidine (VA) , for newly diagnosed acute myeloid leukemia (AML) patients who are elderly or ineligible for intensive chemotherapy. Methods: We retrospectively analyzed the clinical data of 59 newly diagnosed AML patients treated with the VHA or VA regimen at Zhengzhou University Affiliated Cancer Hospital from September 2018 to July 2021. The cohort included 25 males and 34 females, with a median age of 63 years. The overall response rate (ORR) , composite complete remission (CRc) rate [CR+CR with incomplete hematologic recovery (CRi) ], minimal residual disease (MRD) negativity rate, overall survival (OS) , relapse-free survival (RFS) , and adverse events were compared between the two groups. Survival was estimated by the Kaplan-Meier method, and prognostic factors were evaluated using univariable and multivariable Cox regression. Results: At the end of the treatment, the ORR was 88.4% (23/26) in the VHA group [21 CR, 2 partial remissions (PR) ] and 90.9% (30/33) in the VA group (25 CR, 5 PR) , with no significant difference between the groups (P=0.458) . The MRD negativity rates after one cycle of induction were 73.1% (19/26) in the VHA group and 60.6% (20/33) in the VA group, respectively (P=0.315) . In the high-risk subgroup, the composite remission rates after one cycle were 78.6% (11/14) with VHA and 50.0% (5/10) with VA (P=0.143) ; MRD negativity rates were 64.3% (9/14) and 20.0% (2/10) , respectively (P=0.032) . The main adverse events were myelosuppression, gastrointestinal reactions, and infections during neutropenia. Rates of grade 3-4 neutropenia and decreased hemoglobin were similar between groups, whereas grade 3-4 thrombocytopenia was more frequent with VHA than with VA (76.9% vs 45.5%, P=0.015) . With a median follow-up of 13 months (range, 1-59) , 1 year RFS was 69.9% (95% CI: 53.1%-92.2%) with VHA and 55.6% (95% CI: 40.1%-77.1%) with VA (P=0.305) . The 1 year OS rates were 91.7% (95% CI: 77.3%-100.0%) and 58.2% (95% CI: 41.7%-81.4%) , respectively (P=0.024) . Among high risk patients, 1 year RFS and OS were higher with VHA than with VA (RFS: 66.2% vs 37.5%, P=0.046; OS: 85.7% vs 48.0%, P=0.011) . Undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) significantly improved RFS and OS (P=0.027 and 0.047, respectively) . On multivariable analysis, ELN risk classification and MRD negativity after the first cycle were independent prognostic factors for RFS. Treatment regimen (VHA vs VA) , MRD negativity after the first cycle, and receipt of transplantation were independent prognostic factors for OS. Conclusion: VHA provides clinical benefit in newly diagnosed AML patients who are unfit for intensive chemotherapy and in older adults, with particularly favorable outcomes in high risk patients; sequential allo-HSCT confers additional benefit, and associated adverse events are manageable. 目的: 比较高三尖杉酯碱联合维奈克拉、阿扎胞苷(VHA)和VA方案诱导治疗初诊不适合强化疗及老年急性髓系白血病(AML)的疗效及安全性。 方法: 回顾性分析2018年9月至2021年7月郑州大学附属肿瘤医院收治的共计59例应用VHA或VA方案治疗的初诊AML患者临床资料,男25例,女34例,中位年龄63岁,其中26例采用VHA方案治疗,33例采用VA方案治疗。比较两组患者总有效率(ORR)、复合缓解率[完全缓解(CR)+血细胞计数未完全恢复的完全缓解(CRi)]、微小残留病(MRD)、总生存(OS)率、无复发生存(RFS)率及不良反应。采用Kaplan-Meier法和Cox回归模型进行生存预后的单因素及多因素分析。 结果: VHA组ORR为88.4%(23/26),其中CR 21例、部分缓解(PR)2例;VA组ORR为90.9%(30/33),其中CR 25例、PR 5例,两组疗效差异无统计学意义(P= 0.458)。VHA组、VA组1个疗程MRD转阴率分别为73.1%(19/26)和60.6%(20/33),差异无统计学意义(P=0.315)。高危患者中,VHA组、VA组1个疗程复合缓解率分别为78.6%(11/14)和50.0%(5/10),差异无统计学意义(P=0.143);1个疗程MRD转阴率分别为64.3%(9/14)和20.0%(2/10),差异有统计学意义(P=0.032)。患者的不良反应主要是骨髓抑制、胃肠道反应、粒细胞缺乏期感染,VHA组治疗后Ⅲ~Ⅳ级中性粒细胞减少、血红蛋白减少发生率与VA组差异无统计学意义,Ⅲ~Ⅳ级血小板减少的发生率高于VA组(76.9%对45.5%, P=0.015)。中位随访时间13(1~59)个月,VHA组与VA组1年RFS率分别为69.9%(95% CI:53.1%~92.2%)和55.6%(95% CI:40.1%~77.1%),差异无统计学意义(P=0.305)。1年OS率分别为91.7%(95% CI:77.3%~100%)和58.2%(95% CI:41.7%~81.4%),差异有统计学意义(P=0.024)。高危患者中,VHA组的1年RFS率及OS率均高于VA组(RFS:66.2%对37.5%, P=0.046;OS:85.7%对48.0%, P=0.011),接受异基因造血干细胞移植(allo-HSCT)能够明显提高OS率及RFS率(P值分别为0.027、0.047)。多因素分析显示ELN分层、1个疗程MRD转阴为影响RFS的独立预后因素。不同用药方案、1个疗程MRD转阴及是否移植为影响OS的独立预后因素。 结论: VHA方案治疗初诊不适合强化疗及老年AML患者存在临床获益,尤其对于高危患者,序贯allo-HSCT能够获益,且相关不良反应可控。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ai H, Wang Q, Wu HF, et al. [A preliminary analysis of the efficacy and safety of homoharringtonine, venetoclax, and azacitidine for newly diagnosed acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41339047. doi:10.3760/cma.j.cn121090-20241111-00443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。